Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. (Q48308116)

10 February 2018

meta-analysis

0 references

title

Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. (English)

1 reference

10 February 2018

1 reference

A Schmittel

1

1 reference

10 February 2018

T Proebstle

2

1 reference

10 February 2018

R Engenhart-Cabillic

3

1 reference

10 February 2018

C Scheibenbogen

4

1 reference

10 February 2018

A M Geueke

5

1 reference

10 February 2018

E Thiel

6

1 reference

10 February 2018

U Keilholz

7

1 reference

10 February 2018

publication date

1 March 2003

1 reference

10 February 2018

European Journal of Cancer

published in

1 reference

10 February 2018

volume

39

1 reference

10 February 2018

issue

4

1 reference

10 February 2018

page(s)

476-480

1 reference

10 February 2018

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Metastatic pattern of malignant melanoma. A study of 216 autopsy cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Long-term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Fotemustine in the treatment of brain primary tumors and metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900731-1

7 January 2021

10.1016/S0959-8049(02)00731-1

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

12751378

1 reference

10 February 2018